- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
- The Hot Pink Party
You are here
David M. Livingston, MD
Emil Frei Professor of Genetics and Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Goal: To discover non-surgical, non-invasive preventive strategies for BRCA1-driven cancer.
Impact: Dr. Livingston is investigating how the loss of BRCA1 function leads to the development of breast cancer. His work could inform ways to prevent this process and impact the lives of women and men born with a BRCA1 mutation.
What’s next: He and his colleagues will continue to investigate the molecular and biological events that trigger mammary tumor development in women with inherited mutations in BRCA1.
About 72 percent of women with inherited mutations in the BRCA1 gene will develop breast cancer by the age of 80, though it often occurs before the age of 40. Currently, the only preventive measure is to remove the breasts surgically, a particularly difficult decision for young women in their child-bearing years. Dr. Livingston has made significant progress in understanding the earliest steps in the development of BRCA1-driven breast cancer, which he hopes will lead to new, less invasive prevention methods.
Full Research Summary
Research area: Identifying strategies for the early prevention of breast cancer in women with inherited mutations in the BRCA1 gene.
Impact: The BCRA1 gene is a tumor suppressor gene that is in every cell. Some people, however, will inherit a mutated form of the gene that greatly increases their risk of developing breast or ovarian cancer. Currently, the only proven effective way to prevent this from occurring is to surgically remove the breasts and/or ovaries. While the decision to undergo this surgery is difficult for every woman, it is a particularly hard decision for women in their childbearing years to make. Dr. Livingston is studying how mutations in BRCA1 cause normal cells to become cancer cells in order to develop new, less invasive prevention strategies that would spare a woman’s breasts and ovaries.
Current investigation: He and his team have been conducting laboratory studies aimed at discovering molecular changes that promote the development of breast cancer in women with BRCA1 mutations.
What he’s learned so far: Dr. Livingston has identified new molecular and biological steps that contribute to the development of breast cancer cells.
What’s next: He and his colleagues will continue to define these steps in detail—work Dr. Livingston hopes will reveal ways to inhibit the molecular events that trigger BRCA1 mammary tumor development.
Dr. Livingston is a scientist/oncologist whose research has long been focused in the area of molecular cancer science. He received his AB cum laude from Harvard in 1961 and his MD magna cum laude from Tufts Medical School in 1965. He undertook his clinical training in internal medicine at Peter Bent Brigham Hospital and his scientific training at NCI and at Harvard Medical School. He joined the Harvard and DFCI faculty as Assistant Professor of Medicine in 1973 and has been a faculty member at HMS and at DFCI continuously since that time. He is now the Emil Frei Professor of Genetics and Medicine at HMS and DFCI, where he, most recently, served as Chair of the Executive Committee for Research and continues to serve as Director of The Charles A. Dana Division of Human Cancer Genetics and Deputy Director of the Dana-Farber/Harvard Cancer Center. Dr. Livingston was Director and Physician-in-Chief of DFCI from 1991-1995 and Chair, Board of Scientific Advisors at the National Cancer Institute from 1995-1999). He is a member of the Institute of Medicine of the National Academy of Sciences, the National Academy of Sciences, and the American Academy of Arts and Sciences.